Tandem Diabetes Care (NASDAQ:TNDM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, January 5th.

According to Zacks, “Tandem Diabetes Care, Inc. is a medical device company. The Company designs, develops, and commercializes products for people with insulin-dependent diabetes. Its products include t:slim Insulin Delivery System. Tandem Diabetes Care, Inc. is headquartered in San Diego, California. “

A number of other analysts have also commented on the company. Robert W. Baird reaffirmed a “hold” rating and issued a $3.00 target price on shares of Tandem Diabetes Care in a research report on Sunday, November 19th. Wedbush reissued an “outperform” rating and set a $17.00 price objective (down from $50.00) on shares of Tandem Diabetes Care in a report on Tuesday, October 10th. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $15.00 price objective on shares of Tandem Diabetes Care in a report on Friday, October 6th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $11.29.

Tandem Diabetes Care (NASDAQ:TNDM) opened at $2.74 on Friday. Tandem Diabetes Care has a 52 week low of $2.15 and a 52 week high of $26.00. The stock has a market capitalization of $27.73, a PE ratio of -0.14 and a beta of 0.17. The company has a debt-to-equity ratio of -2.70, a current ratio of 1.90 and a quick ratio of 0.88.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its earnings results on Thursday, October 26th. The medical device company reported ($3.09) EPS for the quarter, beating analysts’ consensus estimates of ($3.74) by $0.65. The firm had revenue of $27.00 million during the quarter, compared to the consensus estimate of $25.92 million. During the same period in the previous year, the firm earned ($0.97) earnings per share. The business’s quarterly revenue was up 119.7% on a year-over-year basis. sell-side analysts predict that Tandem Diabetes Care will post -15.15 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the company. Wedbush Securities Inc. grew its holdings in shares of Tandem Diabetes Care by 88.6% in the third quarter. Wedbush Securities Inc. now owns 188,877 shares of the medical device company’s stock valued at $138,000 after acquiring an additional 88,709 shares in the last quarter. Keybank National Association OH grew its holdings in shares of Tandem Diabetes Care by 32.7% in the second quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock valued at $235,000 after acquiring an additional 72,177 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Tandem Diabetes Care by 93.3% in the second quarter. Russell Investments Group Ltd. now owns 581,245 shares of the medical device company’s stock valued at $465,000 after acquiring an additional 280,551 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Tandem Diabetes Care by 2.7% in the second quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock valued at $987,000 after acquiring an additional 32,991 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Marea Informative and is the sole property of of Marea Informative. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.mareainformativa.com/2018/01/31/citigroup-makes-moves-to-close-gender-pay-gap-updated-updated.html.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.